X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse ASTRAZENECA PHARMA with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ASTRAZENECA PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
ADCOCK INGRAM
Jun-14
ASTRAZENECA PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs1,285403-   
Low Rs634291-   
Sales per share (Unadj.) Rs189.6119.9-  
Earnings per share (Unadj.) Rs-0.2-30.2-  
Cash flow per share (Unadj.) Rs3.8-25.0-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs68.694.1-  
Shares outstanding (eoy) m25.00168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.12.9 174.9%   
Avg P/E ratio x-4,712.7-11.5 41,041.7%  
P/CF ratio (eoy) x249.6-13.9 -1,801.3%  
Price / Book Value ratio x14.03.7 379.2%  
Dividend payout %00-   
Avg Mkt Cap Rs m23,98858,557 41.0%   
No. of employees `0001.64.3 36.3%   
Total wages/salary Rs m1,6053,675 43.7%   
Avg. sales/employee Rs Th3,040.24,714.3 64.5%   
Avg. wages/employee Rs Th1,029.2856.1 120.2%   
Avg. net profit/employee Rs Th-3.3-1,187.9 0.3%   
INCOME DATA
Net Sales Rs m4,74020,238 23.4%  
Other income Rs m92142 65.0%   
Total revenues Rs m4,83220,380 23.7%   
Gross profit Rs m-130-3,507 3.7%  
Depreciation Rs m101873 11.6%   
Interest Rs m0548 0.0%   
Profit before tax Rs m-139-4,787 2.9%   
Minority Interest Rs m0-13 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m5299 1.7%   
Profit after tax Rs m-5-5,100 0.1%  
Gross profit margin %-2.7-17.3 15.8%  
Effective tax rate %-3.7-6.2 58.6%   
Net profit margin %-0.1-25.2 0.4%  
BALANCE SHEET DATA
Current assets Rs m2,72614,823 18.4%   
Current liabilities Rs m2,4358,340 29.2%   
Net working cap to sales %6.132.0 19.2%  
Current ratio x1.11.8 63.0%  
Inventory Days Days74111 66.5%  
Debtors Days Days41124 32.9%  
Net fixed assets Rs m1,0358,640 12.0%   
Share capital Rs m5094 53.2%   
"Free" reserves Rs m9420-   
Net worth Rs m1,71615,885 10.8%   
Long term debt Rs m05,582 0.0%   
Total assets Rs m4,15630,008 13.8%  
Interest coverage xNM-7.7-  
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x1.10.7 169.1%   
Return on assets %-0.1-15.2 0.8%  
Return on equity %-0.3-32.1 0.9%  
Return on capital %0-19.8 0.0%  
Exports to sales %5.70-   
Imports to sales %6.50-   
Net fx Rs m-960-   
CASH FLOW
From Operations Rs m-81,727 -0.5%  
From Investments Rs m-146-530 27.5%  
From Financial Activity Rs m8625,066 17.0%  
Net Cashflow Rs m7096,263 11.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.56 Rs / ZAR

Compare ASTRAZENECA PHARMA With: ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare ASTRAZENECA PHARMA With: VENUS REMEDIES  DR. REDDYS LAB  PIRAMAL ENTERPRISES  SUVEN LIFE  ALKEM LABORATORIES  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Feb 23, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS